Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
201 hedge funds and large institutions have $2.29B invested in Genomic Health, Inc. in 2018 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 62 increasing their positions, 52 reducing their positions, and 18 closing their positions.
194% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 18
40% more capital invested
Capital invested by funds: $1.63B → $2.29B (+$656M)
21% more funds holding
Funds holding: 166 → 201 (+35)
19% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 52
17% more call options, than puts
Call options by funds: $5.13M | Put options by funds: $4.4M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.3M |
| 3 |
Renaissance Technologies
New York
|
+$22.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.8M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$124M |
| 2 |
Millennium Management
New York
|
-$30.6M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$19.3M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$5.64M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.89M |
GHDX Hedge Fund Activity: Q3 2018 in Review
201 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2018, worth a combined $2.29B — up 40% from $1.63B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new GHDX positions and 18 closed out — a net gain of 35 holders — while 62 added to existing stakes and 52 trimmed.
The largest buyer was State Street, adding an estimated $25M. The largest seller was Camber Capital Management, exiting entirely with an estimated $124M sold.
- 201 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2018, up from 166 in Q2 2018.
- Funds reported $2.29B of Genomic Health, Inc. stock for Q3 2018, up 40% quarter-over-quarter.
- 53 funds opened new Genomic Health, Inc. positions in Q3 2018 and 18 closed out, a net change of +35 holders.
- The largest Genomic Health, Inc. buyer in Q3 2018 was State Street, an estimated $25M added.
- The largest Genomic Health, Inc. seller in Q3 2018 was Camber Capital Management, an estimated $124M sold.
Based on aggregated 13F filings for Q3 2018.